Despite routine therapies for oral cancers involving multi-disciplinary approaches including surgical resection combined with chemotherapy, radiotherapy or targeted therapy such as cetuximab that targets epidermal growth factor receptor (EGFR) [1, 4, 5], clinical prognostic outcome is far from satisfactory. The gene discussed is EGFR; the disease is lip and oral cavity carcinoma.